Thus, understanding the dysregulation of the PACAP/VIP neuropeptide system in chronic neuroinflammation may pave the way for the development of novel therapeutic strategies for the treatment of MS and/or other relevant neurodegenerative diseases. This evidence concerns the gene VIP and neurodegenerative disease.